2.7% Below Target

The consensus price target for CBT is $89.75, close to the current price of $87.41 (2.7% implied move). Based on 15 analyst estimates, the stock appears fairly valued near current levels.

CBT has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $89.75 implies 2.7% upside from current levels.

With a forward P/E of 13.8392x, CBT trades at a relatively low valuation. The consensus target of $89.75 implies 2.7% appreciation, suggesting the market may be pricing in risks.

The most bullish Wall Street analyst has a price target of $98 for CBT, while the most conservative target is $85. The consensus of $89.75 represents the median expectation. Our quantitative valuation model projects a bull case target of $120 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

CBT is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 7 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month CBT stock forecast based on 15 Wall Street analysts shows a consensus price target of $89.75, with estimates ranging from $85 (bear case) to $98 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $91, with bear/bull scenarios of $57/$120.

Our quantitative valuation model calculates CBT's fair value at $91 (base case), with a bear case of $57 and bull case of $120. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.

CBT trades at a forward P/E ratio of 13.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 14.5x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

CBT appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $89.75 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

CBT analyst price targets range from $85 to $98, a 14% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $89.75 consensus represents the middle ground. Our model's $57-$120 range provides an independent fundamental perspective.